LCTX vs CRSP

For growth investors, Lineage Cell Therapeutics, Inc.

(LCTX) is the stronger pick with 53. 2% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Analysts rate Lineage Cell Therapeutics, Inc. (LCTX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Lineage Cell Therapeutics, Inc.

(LCTX) delivered a total return of -50. 0%, compared to -51. 3% for CRISPR Therapeutics AG (CRSP). Over 10 years, the gap is even starker: CRSP returned +272. 0% versus LCTX's -51. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lineage Cell Therapeutics, Inc.

(LCTX) is the lower-risk stock at 1. 53β versus CRISPR Therapeutics AG's 1. 93β — meaning CRSP is approximately 26% more volatile than LCTX relative to the S&P 500. On balance sheet safety, Lineage Cell Therapeutics, Inc. (LCTX) carries a lower debt/equity ratio of 6% versus 21% for CRISPR Therapeutics AG — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Lineage Cell Therapeutics, Inc.

(LCTX) is pulling ahead at 53. 2% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: CRISPR Therapeutics AG grew EPS -49. 1% year-over-year, compared to -201. 1% for Lineage Cell Therapeutics, Inc.. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lineage Cell Therapeutics, Inc.

(LCTX) is the more profitable company, earning -436. 5% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps -436. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LCTX leads at -251. 6% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — LCTX leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lineage Cell Therapeutics, Inc.

(LCTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. CRISPR Therapeutics AG (CRSP) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LCTX: -51. 2%, CRSP: +272. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LCTX is a small-cap high-growth stock; CRSP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.